MissionIR Articles

July 29, 2020

MissionIRNewsBreaks – Cybin Corp. to Deliver Psychedelic Medicines Targeting Conditions Failed by Big Pharma

Cybin Corp. appears set for opportunity as new data increasingly finds promise in psychedelic medicines. As big pharma has failed to bring groundbreaking drug innovations into the mental-health space, psilocybin — the main compound of…
July 24, 2020

Cybin Corp. Potentially Poised to be First Company Bringing Psychedelic Medicine to Treat Major Depressive Disorder

Psychedelics have shown positive results for treatment of mental health conditions including anxiety, depression, PTSD, addiction, eating disorders, ADHD Big pharma failed to bring drug innovations in mental health space; psychedelics may satisfy vast unmet…
July 22, 2020

Cybin Corp. Emerging as Leader in Growing Psychedelics Space

Clinical studies show serotonergic psychedelics may be effective in treating anxiety, depression, addiction and more Interest in serotonergic psychedelics has dramatically increased within last decade Cybin Corp. is focused on furthering research, development of psilocybin-based…
July 22, 2020

MissionIRNewsBreaks – Cybin Corp. Advancing ‘Fungi-Derived’ Products Amid Mushrooming Interest in Psychedelics

Cybin Corp., a Canada-based, life-sciences company focused on the pharmaceutical development of psychedelic products as well as the functional mushroom market, looks to be in the right place at the right time. A mushrooming interest…